Phase I Study of Gefitinib Plus Celecoxib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Lori J. Wirth(Massachusetts General Hospital), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), Jeffrey C. Lee(Broad Institute), Charles M. Norris, Victoria A. Joshi(Harvard University), Robert I. Haddad(Georgetown University), Xiao‐Jun Zhao(Tongji University), Neal I. Lindeman(Cornell University)
Cited by 104
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k